Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. It develops and distributes devices for minimally invasive surgical and non-surgical bariatric and gastrointestinal procedures that are used by surgeons and gastroenterologists in various settings to provide interventional therapy to patients who suffer from obesity and various co-morbidities associated with obesity, as well as treat various other gastrointestinal conditions. Its products include the OverStitch Endoscopic Suturing System (ESS) and Orbera, an intragastric balloon. The company sells its products primarily in the United States, Canada, Brazil, Costa Rica, Australia, and principal European markets. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone512-279-5100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$64.31 million
Profitability
Miscellaneous
Employees213
OptionableNot Optionable
Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions
What is Apollo Endosurgery's stock symbol?
Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."
How were Apollo Endosurgery's earnings last quarter?
Apollo Endosurgery Inc (NASDAQ:APEN) issued its quarterly earnings data on Wednesday, August, 8th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.10. The biotechnology company earned $15.79 million during the quarter, compared to the consensus estimate of $16.56 million. Apollo Endosurgery had a negative net margin of 56.22% and a negative return on equity of 71.73%. View Apollo Endosurgery's Earnings History.
When is Apollo Endosurgery's next earnings date?
What price target have analysts set for APEN?
3 analysts have issued twelve-month price objectives for Apollo Endosurgery's stock. Their forecasts range from $3.00 to $8.00. On average, they expect Apollo Endosurgery's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 35.5% from the stock's current price. View Analyst Price Targets for Apollo Endosurgery.
What is the consensus analysts' recommendation for Apollo Endosurgery?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Apollo Endosurgery.
What are Wall Street analysts saying about Apollo Endosurgery stock?
Here are some recent quotes from research analysts about Apollo Endosurgery stock:
- 1. According to Zacks Investment Research, "Apollo Endosurgery, Inc. is engaged in designing and manufacturing of medical devices for weight loss solutions and gastrointestinal disorders. The Company's product segment includes ORBERA (R), LAP-BAND (R) and OverStitch(TM). The ORBERA is an Intragastric Balloon System which is a weight loss aid for adults suffering from obesity. The LAP-BAND System is developed for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables endoscopic surgery. It operates primarily in Asia Pacific, European Office, Latin and South America and Costa Rica. Apollo Endosurgery, Inc., formerly known as Lpath, Inc., is headquatered in Austin, Texas. " (2/20/2019)
- 2. Northland Securities analysts commented, "We are upgrading Perform rating. Our PT remains the same. The stock is down a lot from our original downgrade, and we think it is prudent to move to the sidelines. Our core concerns about the story, though, remain. Key Points Our updated outlook is based on the following: Business outlook remains weak. The company has already pre-announced Q4 revenue range of ~$15M (+/- a few hundred thousand), which was lower than consensus of ~$16M." (1/2/2019)
Has Apollo Endosurgery been receiving favorable news coverage?
News articles about APEN stock have been trending neutral this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Apollo Endosurgery earned a news sentiment score of 0.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future.
Who are some of Apollo Endosurgery's key competitors?
Some companies that are related to Apollo Endosurgery include Iradimed (IRMD), Apyx Medical (APYX), Westaim (WEDXF), Vapotherm (VAPO), Cytosorbents (CTSO), Liquidia Technologies (LQDA), Nuvectra (NVTR), T2 Biosystems (TTOO), Sensus Healthcare (SRTS), RenovaCare (RCAR), STRATA Skin Sciences (SSKN), iCAD (ICAD), RA Medical Systems (RMED), Titan Medical (TMDI) and Motus GI (MOTS).
Who are Apollo Endosurgery's key executives?
Apollo Endosurgery's management team includes the folowing people:
- Mr. Todd Newton, CEO & Director (Age 56)
- Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation Partner
- Mr. Anthony Kalloo M.D., Co-Founder and Innovation Partner
- Dr. Robert Hawes M.D., Co-Founder and Innovation Partner
- Dr. Peter Benjamin Cotton M.D., Co-Founder and Innovation Partner
Who are Apollo Endosurgery's major shareholders?
Apollo Endosurgery's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (9.98%), Nantahala Capital Management LLC (8.04%), Gagnon Securities LLC (3.89%), Gagnon Advisors LLC (2.37%), Dimensional Fund Advisors LP (0.56%) and NJ State Employees Deferred Compensation Plan (0.55%). Company insiders that own Apollo Endosurgery stock include A/S Novo, Bret Schwartzhoff, Holdings A/S Novo, Matthew S Crawford, Richard J Meelia, Sciences L P Ptv II, Stefanie L Cavanaugh, Stonepine Capital, LP, Todd Newton and William D Jr Mcclellan. View Institutional Ownership Trends for Apollo Endosurgery.
Which major investors are selling Apollo Endosurgery stock?
Which major investors are buying Apollo Endosurgery stock?
APEN stock was purchased by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Gagnon Securities LLC, Gagnon Advisors LLC, Worth Venture Partners LLC, Strategic Financial Services Inc , Millennium Management LLC, Dimensional Fund Advisors LP and NJ State Employees Deferred Compensation Plan. Company insiders that have bought Apollo Endosurgery stock in the last two years include Bret Schwartzhoff, Matthew S Crawford, Richard J Meelia, Sciences L P Ptv II, Stefanie L Cavanaugh, Stonepine Capital, LP, Todd Newton and William D Jr Mcclellan. View Insider Buying and Selling for Apollo Endosurgery.
How do I buy shares of Apollo Endosurgery?
Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apollo Endosurgery's stock price today?
One share of APEN stock can currently be purchased for approximately $3.69.
How big of a company is Apollo Endosurgery?
Apollo Endosurgery has a market capitalization of $80.79 million and generates $64.31 million in revenue each year. The biotechnology company earns $-27,290,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Apollo Endosurgery employs 213 workers across the globe.
What is Apollo Endosurgery's official website?
How can I contact Apollo Endosurgery?
Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]
MarketBeat Community Rating for Apollo Endosurgery (NASDAQ APEN)
MarketBeat's community ratings are surveys of what our community members think about Apollo Endosurgery and other stocks. Vote "Outperform" if you believe APEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
